Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.32 HKD | 0.00% | -4.48% | -67.68% |
Sales 2023 | 103M 14.2M 111M | Sales 2024 * | 130M 17.95M 140M | Capitalization | 126M 17.41M 136M |
---|---|---|---|---|---|
Net income 2023 | -379M -52.32M -409M | Net income 2024 * | -250M -34.51M -270M | EV / Sales 2023 | 3.76 x |
Net cash position 2023 | 4.44M 613K 4.79M | Net cash position 2024 * | - 0 0 | EV / Sales 2024 * | 0.97 x |
P/E ratio 2023 |
-1.03
x | P/E ratio 2024 * |
-0.5
x | Employees | 100 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 89.98% |
Latest transcript on CANbridge Pharmaceuticals Inc.
1 week | -4.48% | ||
Current month | -25.58% | ||
1 month | -28.09% | ||
3 months | -23.81% | ||
6 months | -70.64% | ||
Current year | -67.68% |
Managers | Title | Age | Since |
---|---|---|---|
James Xue
CEO | Chief Executive Officer | 55 | 18-01-29 |
Glenn Hassan
DFI | Director of Finance/CFO | 46 | 19-04-01 |
Gerald Cox
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Edward Hu
BRD | Director/Board Member | 61 | 22-07-04 |
James Geraghty
BRD | Director/Board Member | 69 | 18-07-17 |
Peng Kuan Chan
BRD | Director/Board Member | 60 | 21-06-10 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-28 | 0.32 | 0.00% | 2 000 |
24-05-27 | 0.32 | -7.25% | 204,000 |
24-05-24 | 0.345 | -1.43% | 7,000 |
24-05-23 | 0.35 | +4.48% | 37,000 |
24-05-22 | 0.335 | -2.90% | 152,000 |
Delayed Quote Hong Kong S.E., May 28, 2024 at 04:08 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-67.68% | 17.41M | |
+16.34% | 79.03B | |
+8.65% | 8.78B | |
-16.33% | 4.83B | |
+51.22% | 4.65B | |
+2.18% | 3.89B | |
+20.51% | 2.34B | |
-26.79% | 2.18B | |
+15.12% | 2.11B | |
-36.56% | 2B |
- Stock Market
- Equities
- 1228 Stock